Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Cognition Disorders × Lovastatin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neurofibromatosis 1 5 Prostatic Neoplasms 2 Breast Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 1 Radiation Injuries 1 Ovarian Neoplasms 1 Oropharyngeal Neoplasms 1 Noonan Syndrome 1 Nasopharyngeal Carcinoma 1 Mouth Neoplasms 1 Melanoma 1 Leukemia, Myeloid, Acute 1 Learning Disabilities 1 Laryngeal Neoplasms 1 Inhibition, Psychological 1 Hypopharyngeal Neoplasms 1 Dyslexia 1 Cognition Disorders 1 Carcinoma, Ovarian Epithelial 1 Carcinoma 1 Breast Carcinoma In Situ 1 Autism Spectrum Disorder 1

Interventions

Transcranial Direct Current Stimulation 1 Spermine Synthase 1 Radiosurgery 1 Palliative Care 1 Modafinil 1 Methods 1 Mental Status and Dementia Tests 1 Magnetic Resonance Spectroscopy 1 Lovastatin 1 Lomustine 1 Lamotrigine 1 Functional Status 1 Exercise 1 Drug Therapy 1 Donepezil 1 DNA Methylation 1 Cognitive Training 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03504501 2023-11-30

SynCoRAS

Technical University of Munich

Phase 2 Terminated

Cognition Disorders, Neurofibromatosis 1, Noonan Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡